Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Journal
Lancet (London, England)
Journal Volume
399
Journal Issue
10326
Date Issued
2022-02-19
Author(s)
Wykoff, Charles C
Abreu, Francis
Adamis, Anthony P
Basu, Karen
Eichenbaum, David A
Haskova, Zdenka
Lin, Hugh
Loewenstein, Anat
Mohan, Shaun
Pearce, Ian A
Sakamoto, Taiji
Schlottmann, Patricio G
Silverman, David
Sun, Jennifer K
Wells, John A
Willis, Jeffrey R
Tadayoni, Ramin
Abstract
To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial growth factor-A bispecific antibody.
Type
journal article